Literature DB >> 16294217

Recent progress in the battle between oncolytic viruses and tumours.

Kelley A Parato1, Donna Senger, Peter A J Forsyth, John C Bell.   

Abstract

In the past 5 years, the field of oncolytic virus research has matured significantly and is moving past the stage of being a laboratory novelty into a new era of preclinical and clinical trials. What have recent anticancer trials of oncolytic viruses taught us about this exciting new line of therapeutics?

Entities:  

Mesh：

Year:  2005        PMID： 16294217     DOI： 10.1038/nrc1750

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  205 in total

1.  Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells.

Authors:  Xinping Fu; Armando Rivera; Lihua Tao; Bart De Geest; Xiaoliu Zhang
Journal:  Mol Ther       Date:  2011-12-06       Impact factor: 11.454

2.  Interfering with tumor pathways that augment viral oncolysis.

Authors:  John C Bell
Journal:  Mol Ther       Date:  2011-12       Impact factor: 11.454

Review 3.  The good viruses: viral mutualistic symbioses.

Authors:  Marilyn J Roossinck
Journal:  Nat Rev Microbiol       Date:  2011-01-04       Impact factor: 60.633

4.  Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.

Authors:  Alison Tedcastle; Sam Illingworth; Alice Brown; Leonard W Seymour; Kerry D Fisher
Journal:  Mol Ther       Date:  2015-12-28       Impact factor: 11.454

5.  Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

Authors:  Marianne M Stanford; Mae Shaban; John W Barrett; Steven J Werden; Philippe-Alexandre Gilbert; Joe Bondy-Denomy; Lisa Mackenzie; Kevin C Graham; Ann F Chambers; Grant McFadden
Journal:  Mol Ther       Date:  2007-11-13       Impact factor: 11.454

6.  Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

7.  Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Authors:  Xue Qing Lun; Hongyuan Zhou; Tommy Alain; Beichen Sun; Limei Wang; John W Barrett; Marianne M Stanford; Grant McFadden; John Bell; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

8.  Hypoxia enhances the replication of oncolytic herpes simplex virus.

Authors:  Manish K Aghi; Ta-Chiang Liu; Samuel Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

9.  Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.

Authors:  Kimberly P Kicielinski; E Antonio Chiocca; John S Yu; George M Gill; Matt Coffey; James M Markert
Journal:  Mol Ther       Date:  2014-02-20       Impact factor: 11.454

10.  Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

Authors:  Thi Lien-Anh Nguyên; Hesham Abdelbary; Meztli Arguello; Caroline Breitbach; Simon Leveille; Jean-Simon Diallo; Amber Yasmeen; Tarek A Bismar; David Kirn; Theresa Falls; Valerie E Snoulten; Barbara C Vanderhyden; Joel Werier; Harold Atkins; Markus J V Vähä-Koskela; David F Stojdl; John C Bell; John Hiscott
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.